Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sreya Duttagupta
Observed name:
Duttagupta, Sreya
Institutions:
Centre Hospitalier de l’Université de Montréal,
Université de Montréal
Observed institutions:
Centre Hospitalier de l’Université de Montréal,
KIIT University,
Université de Montréal
ORCID:
0009-0008-8219-3737
Observed ORCID:
0009-0008-8219-3737
OpenAlex ID:
A5107219627
Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial
2026
·
Sreya Duttagupta
, Meriem Messaoudene
, et al.
·
Nature Medicine
·
121
PDF
Efficacy of amino acids in sports nutrition- review of clinical evidences
2024
·
Sreya Duttagupta
, Niladri Krishna Roy
, et al.
·
Food Research International
·
31
The Gut Microbiome from a Biomarker to a Novel Therapeutic Strategy for Immunotherapy Response in Patients with Lung Cancer
2023
·
Sreya Duttagupta
, Taiki Hakozaki
, et al.
·
Current Oncology
·
30
PDF
Abstract CT258: Phase II trial of fecal microbiota transplantation in combination with ipilimumab and nivolumab in patients with advanced cutaneous melanoma (FMT-LUMINate trial)
2024
·
Sreya Duttagupta
, Meriem Messaoudene
, et al.
·
Cancer Research
·
13
Abstract 2210: Microbiome profiling reveals that fecal microbiota transplantation (FMT) modulates response and toxicity when combined with immunotherapy in patients with lung cancer and melanoma (FMT-LUMINate NCT04951583)
2025
·
Sreya Duttagupta
, Meriem Messaoudene
, et al.
·
Cancer Research
·
8
Abstract 2223: Phase I clinical trial combining camu camu prebiotic enriched with castalagin modulates bile acids and metabolites in combination with cancer immunotherapy in patients with treatment-naïve lung cancer and PD-1 refractory melanoma (NCT05303493)
2025
·
Jade Maillou
, Reilly Pidgeon
, et al.
·
Cancer Research
·
3
Deciphering bacterial donor-host compatibility in patients with cancer undergoing fecal microbial transplantation
2026
·
Duttagupta, Sreya
·
Papyrus : Institutional Repository (Université de Montréal)
PDF
Abstract CT182: Camu camu plus nivolumab/ipilimumab (N/I) as first-line therapy for metastatic renal cell carcinoma (mRCC): A randomized phase I trial
2026
·
Regina Barragan Carrillo
, Miguel Zugman
, et al.
·
Cancer Research
Show more works
View as search
Works count:
8
Citation count:
206
H-index:
5
I10-index:
4
Year
Topic
Type